Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ...

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and ...

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T ...

Collaboration with intent to validate Cellares’ Cell Shuttle platform for manufacturing of CABA-201, Cabaletta Bio’s fully human CD19-CAR T product candidate, which is being evaluated in ...